32 studies found for:    " January 24, 2009":" February 23, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring
Conditions: Human Immunodeficiency Virus;   HIV Infections
Interventions: Drug: Reducing dose of Lopinavir;   Drug: Reducing dose of efavirenz
2 Completed Video-based Counseling & Rapid HIV Testing for Teens
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Video;   Behavioral: in-person HIV pre-test counseling
3 Unknown  A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication
Conditions: HIV-1;   HIV Infections
Interventions: Other: VircoType HIV-1 genotypic interpretation;   Other: Local Expert Review of HIV Genotypic resistance testing
4 Unknown  Positive Lifestyles Using Safety
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Pre-Release (Group 1);   Behavioral: Post-release (Group 2)
5 Completed
Has Results
Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Conditions: Hepatitis C;   Human Immunodeficiency Virus;   HIV Infections
Intervention: Drug: Pegylated interferon alfa-2a + Ribavirin
6 Unknown  Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men
Conditions: HIV Infection;   Cardiovascular Risk;   HIV Infections
Interventions: Other: Omega-3 study meal;   Other: Saturated fat study meal
7 Active, not recruiting
Has Results
Behavioral Intervention to Reduce Sexual and Injection Risks Among Female Sex Workers Who Also Inject Drugs in Mexico
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Interactive injection and sexual risk intervention;   Behavioral: Interactive Sexual Risk Intervention;   Behavioral: Interactive Injection Risk Intervention
8 Completed
Has Results
A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
Condition: Human Immunodeficiency Virus Type 1
Interventions: Drug: TMC310911 75 mg twice daily;   Drug: TMC310911 150 mg twice daily;   Drug: TMC310911 300 mg twice daily;   Drug: TMC310911 300 mg once daily;   Drug: Ritonavir 100 mg twice daily;   Drug: Ritonavir 100 mg once daily
9 Completed Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV
Conditions: HIV;   HIV Infections
Interventions: Biological: ZFN modified T cells;   Other: Structured Treatment Interruption
10 Completed Transitions: Linkages From Jail To Community
Conditions: HIV;   Substance Abuse;   HIV Infections
Interventions: Behavioral: Intensive Case Management;   Drug: Buprenorphine;   Behavioral: Money Management
11 Completed Study of Impacts of Food Supplementation on Malnourished HIV-Infected Adults in Kenya
Conditions: HIV;   Malnutrition;   HIV Infections
Interventions: Dietary Supplement: fortified blended flour - Insta Foundation Plus (with whey protein concentrate);   Other: nutrition counseling
12 Completed Cell Phone Intervention to Support Antiretroviral Therapy (ART) Adherence in Kenya
Conditions: HIV;   AIDS;   HIV Infections
Intervention: Other: Cell Phone Intervention
13 Active, not recruiting Effect of Raltegravir on Endothelial Function in HIV-Infected Patients
Conditions: HIV Infection;   Inflammation;   Cardiovascular Disease;   HIV Infections
Interventions: Drug: raltegravir;   Drug: Placebo
14 Completed
Has Results
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Conditions: HIV-1;   HIV Infections
Interventions: Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine;   Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose);   Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
15 Completed A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
Conditions: HIV-1;   HIV Infections
Interventions: Biological: V520;   Biological: Comparator: V520 (1x10^9 vp/d);   Biological: Comparator: V520 (1x10^10 vp/d);   Biological: Comparator: Placebo
16 Active, not recruiting Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension
Conditions: HIV Infection;   Pulmonary Hypertension;   Endothelial Function;   HIV Infections
Intervention:
17 Active, not recruiting A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
Conditions: HIV-1 Infection;   HIV Infections
Interventions: Biological: mRNA-transfected autologous dendritic cells;   Biological: Autologous dendritic cells not transfected with mRNA.
18 Completed ID and Testing Via Friendship Networks
Conditions: Asymptomatic HIV;   HIV Infections
Interventions: Other: Index Recruiter;   Other: Friendship Network Member
19 Completed HIV Prevention Program for African American Teen Males
Conditions: HIV Infections;   Sexually Transmitted Infections
Interventions: Behavioral: Male Sexual Health Program;   Behavioral: Focus on the Future Program
20 Completed
Has Results
Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
Conditions: Human Immunodeficiency Virus Type 1 (HIV-1);   HIV Infections
Interventions: Drug: Voriconazole;   Drug: Atazanavir;   Drug: Ritonavir

Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results
Indicates status has not been verified in more than two years